BioAtla (BCAB) EBT (2020 - 2026)

BioAtla (BCAB) has reported EBT for 7 consecutive years, with $232000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 101.26% year-over-year to $232000.0; the trailing twelve-month figure through Jun 2026 stood at -$31.9 million (up 48.47% YoY), and the FY2025 full-year result was -$58.5 million, up 17.16% from the prior year.
• EBT grew to $232000.0 in Q2 2026 per BCAB's latest filing, from -$9.3 million in the prior quarter.
• Across five years, EBT topped out at $232000.0 in Q2 2026 and bottomed at -$35.7 million in Q2 2023.
• Historically, EBT has averaged -$20.4 million across 5 years, with a median of -$22.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: EBT retreated 29.73% in 2022, then jumped 101.26% in 2026.
• Over 5 years, EBT stood at -$27.5 million in 2022, then rose by 2.24% to -$26.9 million in 2023, then soared by 41.67% to -$15.7 million in 2024, then surged by 41.48% to -$9.2 million in 2025, then soared by 102.53% to $232000.0 in 2026.
• According to Business Quant data, EBT over the past three periods registered $232000.0, -$9.3 million, and -$9.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.